Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer : A new independent and favorable prognostic marker

• Published in: Cancer research (Chicago, Ill.) Vol. 61; no. 21; pp. 7811 - 7818
• Main Authors: YOUSEF, George M, KYRIAKOPOULOU, Lianna G, RICHIARDI, Giovanni, MASSOBRIO, Marco, DIAMANDIS, Eleftherios P, KATSAROS, Dionyssios, SCORILAS, Andreas, FRACCHIOLI, Stefano, GHIRINGHELLO, Bruno, ZARGHOONI, Maryam, CHANG, Albert, DIAMANDIS, Maria, GIARDINA, Giorgio, HARTWICK, Warren J
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01-11-2001
• Subjects: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biological and medical sciences; Biomarkers, Tumor - biosynthesis; Biomarkers, Tumor - genetics; Estrogens - physiology; Female; Female genital diseases; Gene Expression Regulation, Neoplastic; Gynecology. Andrology. Obstetrics; Humans; Immunohistochemistry; Kallikrein; Kallikreins - biosynthesis; Kallikreins - genetics; KLK9 gene; Medical sciences; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Progestins - physiology; Prognosis; Survival Rate; Tumors; Up-Regulation; Histological grading; Human; Carcinoma; Prognosis; Tumoral tissue; Biological marker; Malignant tumor; Gene expression; In vitro; Female genital diseases; Ovarian diseases; Ovary; Clinical stage; Female; Predictive factor; Quantitative analysis
• ISSN: 0008-5472; 1538-7445

Many members of the human kallikrein gene family were found to be differentially expressed in various malignancies and some are useful cancer diagnostic/prognostic markers. KLK9 is a newly discovered human kallikrein gene that is expressed in several tissues including thymus, testis, spinal cord, salivary gland, ovary, and skin. Like other kallikreins, the KLK9 gene was found to be regulated by steroid hormones in cancer cell lines. Our purpose is to examine whether quantitative analysis of KLK9 expression has prognostic value in ovarian cancer. We studied the expression of KLK9 by quantitative reverse transcription-PCR in 168 consecutive ovarian tumors of different stages, grades, and histological types, and correlated the expression with clinicopathological parameters, response to chemotherapy, and patients' survival. We found that KLK9 expression was significantly higher in patients with early disease stages (I or II; P = 0.044) and in patients with optimal debulking (P = 0.019). Kaplan-Meier survival curves demonstrated that patients with KLK9-positive tumors have substantially longer progression-free and overall survival (P < 0.001 and P = 0.016, respectively). When the Cox proportional hazard regression analysis was applied to subgroups of patients, KLK9 expression was found to be a significant predictor of progression-free survival in the subgroup of patients with low-grade tumors [hazard ratio (HR), 0.13; P = 0.0015], early stage (HR, 0.099; P = 0.031); and those with optimal debulking (HR, 0.26; P = 0.012). After adjusting for other known prognostic variables, KLK9 retained its independent prognostic value in all of these subgroups of patients. A negative correlation was found between the expression levels of CA125 and KLK9 (rs, 0.350; P = 0.002). Our results indicate that KLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines. Immmunohistochemically, human kallikrein protein (hK9) was localized in the cytoplasm, but not in the nuclei, of the epithelial cells of ovarian cancer tissues. We conclude that KLK9 is a potential new independent favorable prognostic marker for early stage, low-grade, optimally debulked ovarian cancer patients.